SecBot SecBot
8-K ·Filed Jul 6, 2026

REGN

REGENERON PHARMACEUTICALS, INC.
NEUTRAL
Impact 4/10
Horizonimmediate Processed4mo ago SEC0001104659-26-080562
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The ~$1.00 EPS headwind from this non-cash IPR&D charge is a one-time deal-related item, not an operational deterioration. Watch for the full Q2 2026 earnings release for underlying revenue and Dupixent/EYLEA HD trends, the charge will create a headline EPS miss vs the $8.47 Street consensus, but the core business trajectory (Q1 revenue +19% YoY, $3B buyback) remains intact. The prior Q1 filing showed strong momentum, so this pre-announcement is noise, not a signal change.

DirectionNeutral
Confidencehigh
Horizonimmediate

Drugs in focus

REGN drug pipeline →

Otarmeni

● Neutral Named in this 8-K
Impact
Phase
Approved (accelerated approval)
Time to market
Already FDA-approved (April 23, 2026); commercially available in the U.S.
Next catalyst
BLA filing · 2026

What to watchOtarmeni's approval binary has passed and the drug is provided free in the U.S. under a government pricing deal, so it generates zero direct revenue. For Regeneron investors, EMA approval (under accelerated assessment review) is a modest upside tailwind but immaterial given the ultra-rare indication and free-access model. The stock's bigger catalysts are Eylea HD dosing expansions, the garetosmab PDUFA (August 2026), and Dupixent pipeline growth, not this drug.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$649.81
T+0 close · Jul 6, 2026 · via day close
Latest settled
+15.50%
T+60 · $750.51
Vs SPY
+13.78%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 6 $649.81entry
  2. T+1 · 4mo ago +4.07%α +4.54% · $676.23
  3. T+5 · 4mo ago +2.26%α +1.78% · $664.52
  4. T+20 · 4mo ago +17.36%α +17.93% · $762.63
  5. T+60 · 7w ago +15.50%α +13.78% · $750.51
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Regeneron filed an 8-K pre-announcing an expected ~$127M pre-tax acquired IPR&D charge for Q2 2026, which will reduce GAAP and non-GAAP EPS by approximately $1.00 per diluted share. This is a non-cash charge tied to collaboration and licensing payments, not an operational deterioration, but it signals ongoing deal activity and will create a one-time headwind to reported Q2 earnings.

Key Facts

  • Regeneron expects a ~$127M pre-tax acquired IPR&D charge in Q2 2026 from collaboration and licensing up-front/opt-in payments.
  • The charge is expected to reduce GAAP and non-GAAP EPS by approximately $1.00 per diluted share in Q2 2026.
  • The charge is non-cash and deal-related, not an operational deterioration, Regeneron does not forecast such charges due to their uncertain timing.
  • Q2 2026 results are not yet finalized and remain subject to closing procedures.
  • The prior Q1 2026 quarter showed strong operational momentum: total revenue +19% YoY to $3.6B, non-GAAP EPS +15% to $9.47, and a new $3B buyback authorization.

Financial Impact

~$127M pre-tax IPR&D charge, ~$1.00 per diluted share negative impact on GAAP and non-GAAP EPS for Q2 2026

GAAP net income per diluted sharenon-GAAP net income per diluted share

Risk Factors

  • Q2 2026 GAAP and non-GAAP EPS will be reduced by ~$1.00 due to the IPR&D charge, potentially causing a headline miss vs consensus.
  • The charge is non-cash and deal-related, but momentum traders may react negatively to the EPS headwind.
  • Q2 results are not yet finalized, actuals could differ from the preliminary estimate.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
71% bullish (38 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-080562
Document: 0001104659-26-080562-index-headers.html0001104659-26-080562
Document: 0001104659-26-080562-index.html0001104659-26-080562
Document: 0001104659-26-080562.txt0001104659-26-080562
8-K Data (Synthetic)0001104659-26-080562

Track record

53 reports on REGN

Performance horizon

11 of 17 bullish or bearish reports moved the stock their way by T+20. Best: +31.76% at T+20 after the Oct 6, 2026 report. 17 of 21 went positive at some point.

Filters
  1. Nov 16, 2026today 144 Neutral 2/10 Entry $951.23 Now $952.40 +0.12% settles Dec 16
  2. Nov 16, 2026today 144 Neutral 2/10 Entry $948.00 Now $952.40 +0.46% settles Dec 16
  3. Nov 12, 20264d ago Press Release Bullish 5/10 Entry $955.47 Now $952.40 −0.32% settles Dec 14
  4. Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
  5. Nov 5, 202611d ago Insider Cluster Neutral 3/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
  6. Nov 4, 202612d ago 144 Neutral 1/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
  7. Nov 4, 202612d ago 144 Neutral 2/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
  8. Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
  9. Nov 3, 202613d ago 144 Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
  10. Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
Showing 10 of 53

US Market Status

Market Closed · Opens Wed (9h 41m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 6, 2026